Market Closed -
Nasdaq
04:00:03 2024-07-12 pm EDT
|
5-day change
|
1st Jan Change
|
39.75
USD
|
+6.00%
|
|
+28.72%
|
0.00%
|
Fiscal Period: December |
2024
|
2025
|
2026
|
---|
Capitalization
1 |
6,554
|
-
|
-
|
Enterprise Value (EV)
1 |
6,457
|
6,477
|
6,568
|
P/E ratio
|
-8.63
x
|
-28.8
x
|
-52.7
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
9.49
x
|
7.11
x
|
5.33
x
|
EV / Revenue
|
9.35
x
|
7.02
x
|
5.34
x
|
EV / EBITDA
|
-55.7
x
|
-196
x
|
65.9
x
|
EV / FCF
|
-35.2
x
|
-161
x
|
140
x
|
FCF Yield
|
-2.84%
|
-0.62%
|
0.71%
|
Price to Book
|
91.5
x
|
1,048
x
|
105
x
|
Nbr of stocks (in thousands)
|
164,833
|
-
|
-
|
Reference price
2 |
39.76
|
39.76
|
39.76
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
531.8
|
690.5
|
922.1
|
1,230
|
EBITDA
1 |
-
|
-116
|
-33.01
|
99.72
|
EBIT
1 |
-
|
-294.3
|
-104.3
|
20.9
|
Operating Margin
|
-
|
-42.63%
|
-11.31%
|
1.7%
|
Earnings before Tax (EBT)
1 |
-
|
-560.3
|
-163.9
|
-73.8
|
Net income
1 |
-214.1
|
-746.8
|
-231.4
|
-134.4
|
Net margin
|
-40.26%
|
-108.16%
|
-25.1%
|
-10.92%
|
EPS
2 |
-
|
-4.606
|
-1.378
|
-0.7548
|
Free Cash Flow
1 |
-
|
-183.6
|
-40.27
|
46.93
|
FCF margin
|
-
|
-26.59%
|
-4.37%
|
3.82%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
47.07%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
Announcement Date
|
5/20/24
|
-
|
-
|
-
|
Fiscal Period: December |
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
160.3
|
179.2
|
206.3
|
199.3
|
223.9
|
EBITDA
1 |
-37.69
|
-25.69
|
-8.815
|
-6.55
|
-4.15
|
EBIT
1 |
-119.6
|
-40.41
|
-23.16
|
-23.99
|
-18.11
|
Operating Margin
|
-74.62%
|
-22.55%
|
-11.23%
|
-12.03%
|
-8.09%
|
Earnings before Tax (EBT)
1 |
-389.9
|
-60.93
|
-44.63
|
-54.75
|
-53.55
|
Net income
1 |
-557.2
|
-72.19
|
-55.06
|
-57.17
|
-54.73
|
Net margin
|
-347.61%
|
-40.29%
|
-26.69%
|
-28.68%
|
-24.45%
|
EPS
2 |
-3.380
|
-0.4323
|
-0.3336
|
-0.3250
|
-0.3200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
14.1
|
Net Cash position
1 |
-
|
96.8
|
77.2
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
0.1413
x
|
Free Cash Flow
1 |
-
|
-184
|
-40.3
|
46.9
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-118%
|
14.1%
|
ROA (Net income/ Total Assets)
|
-
|
-26.3%
|
-9.72%
|
1.83%
|
Assets
1 |
-
|
2,837
|
2,382
|
-7,358
|
Book Value Per Share
2 |
-
|
0.4300
|
0.0400
|
0.3800
|
Cash Flow per Share
2 |
-
|
-1.670
|
-1.140
|
-
|
Capex
1 |
-
|
12.8
|
9.75
|
9.73
|
Capex / Sales
|
-
|
1.86%
|
1.06%
|
0.79%
|
Announcement Date
|
5/20/24
|
-
|
-
|
-
|
Last Close Price
39.76
USD Average target price
45.29
USD Spread / Average Target +13.90% Consensus |
1st Jan change
|
Capi.
|
---|
| 0.00% | 6.55B | | +22.10% | 46.55B | | +46.45% | 41.84B | | -3.12% | 40.84B | | +36.10% | 32.95B | | -6.30% | 28.27B | | +18.71% | 27.78B | | +46.15% | 14.26B | | +44.52% | 13.69B | | +0.19% | 12.18B |
Other Biotechnology & Medical Research
|